Interactions between osteopontin and vascular endothelial growth factor: Implications for cancer

被引:37
|
作者
Ramchandani, Divya [1 ]
Weber, Georg F. [1 ]
机构
[1] Univ Cincinnati, James L Winkle Coll Pharm, Cincinnati, OH 45267 USA
来源
关键词
Angiogenesis; Hypoxia; Apoptosis; Cancer; Vascular disease; Immune system; MARROW STROMAL CELLS; BONE MORPHOGENETIC PROTEINS; EPITHELIAL OVARIAN-CANCER; BIOACTIVE GLASS SCAFFOLDS; GENE-EXPRESSION ANALYSIS; BREAST-TUMOR GROWTH; IN-VITRO; OSTEOGENIC DIFFERENTIATION; EXTRACELLULAR-MATRIX; PROSTATE-CANCER;
D O I
10.1016/j.bbcan.2015.02.003
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
For this comprehensive review, 257 publications with the keywords "osteopontin" or "OPN" and "vascular endothelial growth factor" or "VEGF" in PubMed were screened (time frame from year 1996 to year 2014). 37 articles were excluded because they were not focused on the interactions between these molecules, and papers relevant for transformation-related phenomena were selected. Osteopontin (OPN) and vascular endothelial growth factor (VEGF) are characterized by a convergence in function for regulating cell motility and angiogenesis, the response to hypoxia, and apoptosis. Often, they are co-expressed or one molecule induces the other, however, in some settings OPN-associated pathways and VEGF-associated pathways are distinct. Their relationships affect the pathogenesis in cancer, where they contribute to progression and angiogenesis and serve as markers for poor prognosis. The inhibition of OPN may reduce VEGF levels and suppress tumor progression. In vascular pathologies, these two cytokines mediate remodeling, but may also perpetuate inflammation and narrowing of the arteries. OPN and VEGF are elevated and contribute to vascularization in inflammatory diseases. (C) 2015 Elsevier B.V. All rights reserved.
引用
收藏
页码:202 / 222
页数:21
相关论文
共 50 条
  • [31] Molecular docking and analysis of interactions between vascular endothelial growth factor (VEGF) and SPARC protein
    Chandrasekaran, Vasu
    Ambati, Jayakrishna
    Ambati, Balamurali K.
    Taylor, Ethan Will
    JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2007, 26 (04): : 775 - 782
  • [32] Role of vascular endothelial growth factor and vascular endothelial growth factor receptors in vascular development
    Carmeliet, P
    Collen, D
    VASCULAR GROWTH FACTORS AND ANGIOGENESIS, 1999, 237 : 133 - 158
  • [33] Targeting vascular endothelial growth factor in colorectal cancer
    Berlin, JD
    ONCOLOGY-NEW YORK, 2002, 16 (08): : 13 - 15
  • [34] Vascular endothelial growth factor and breast cancer risk
    Reeves, Katherine W.
    Ness, Roberta B.
    Stone, Roslyn A.
    Weissfeld, Joel L.
    Vogel, Victor G.
    Powers, Robert W.
    Modugno, Francesmary
    Cauley, Jane A.
    CANCER CAUSES & CONTROL, 2009, 20 (03) : 375 - 386
  • [35] Vascular endothelial growth factor as a therapeutic target in cancer
    Bergsland, EK
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2004, 61 (21) : S4 - S11
  • [36] Transcriptional regulation of vascular endothelial growth factor in cancer
    Loureiro, RMB
    D'Amore, PA
    CYTOKINE & GROWTH FACTOR REVIEWS, 2005, 16 (01) : 77 - 89
  • [37] Vascular endothelial growth factor in ovarian cancer.
    Hazelton D.A.
    Hamilton T.C.
    Current Oncology Reports, 1999, 1 (1) : 59 - 63
  • [38] Vascular endothelial growth factor inhibitors in colon cancer
    Diaz-Rubio, Eduardo
    NEW TRENDS IN CANCER FOR THE 21ST CENTURY, 2ND EDITION, 2006, 587 : 251 - 275
  • [39] Vascular Endothelial Growth Factor A Inhibition in Gastric Cancer
    Park, Do Joong
    Thomas, Nicholas J.
    Yoon, Changhwan
    Yoon, Sam S.
    GASTRIC CANCER, 2015, 18 (01) : 33 - 42
  • [40] Vascular Endothelial Growth Factor A Inhibition in Gastric Cancer
    Do Joong Park
    Nicholas J. Thomas
    Changhwan Yoon
    Sam S. Yoon
    Gastric Cancer, 2015, 18 : 33 - 42